A Phase II Study of Panobinostat in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Highlights • Phase II data of Panobinostat in myelofibrosis demonstrates clinical activity. • Panobinostat for myelofibrosis is effective in reducing spleen volume. • Panobinostat requires prolonged low doses to observe clinical effect. • Study of combination panobinostat and ruxolitinib for myelofi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2017-02, Vol.53, p.13-19
Hauptverfasser:	Mascarenhas, John, Sandy, Lonette, Lu, Min, Yoon, James, Petersen, Bruce, Zhang, David, Ye, Fei, Newsom, Carrie, Najfeld, Vesna, Hochman, Tsivia, Goldberg, Judith D, Hoffman, Ronald
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Epigenetics Female Hematology, Oncology and Palliative Medicine Histone deacetylase inhibitor Histone Deacetylase Inhibitors - administration & dosage Humans Hydroxamic Acids - administration & dosage Indoles - administration & dosage Janus Kinase 2 - genetics Male Middle Aged Myelofibrosis Organ Size Panobinostat Phase II Polycythemia Vera - drug therapy Primary Myelofibrosis - drug therapy Spleen - pathology Thrombocythemia, Essential - drug therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Phase II data of Panobinostat in myelofibrosis demonstrates clinical activity. • Panobinostat for myelofibrosis is effective in reducing spleen volume. • Panobinostat requires prolonged low doses to observe clinical effect. • Study of combination panobinostat and ruxolitinib for myelofibrosis is warranted.
ISSN:	0145-2126 1873-5835
DOI:	10.1016/j.leukres.2016.11.015